Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of 1-deoxynojirimycin for preparing diabete and disney disease drug

A technology of deoxynojirimycin, diabetic nephropathy, applied in the field of pharmacy

Inactive Publication Date: 2005-12-21
TONGJI UNIV
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report at home and abroad on the effect of DNJ on the treatment of diabetic nephropathy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1-deoxynojirimycin for preparing diabete and disney disease drug
  • Use of 1-deoxynojirimycin for preparing diabete and disney disease drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Effect of 1-deoxynojirimycin on proliferation of rat mesangial cells cultured in high glucose

[0028] 1. Materials and Reagents

[0029] The rat mesangial cell line was donated by Professor Mei Changlin, Department of Nephrology, Shanghai Changzheng Hospital Affiliated to Second Military Medical University. Reagents: 1-deoxynojirimycin is a product of Wako, Japan; MTT and DMSO are products of AMRESCO; Trypan Blue is a product of Sigma, USA. The microplate reader was produced by Labsystem MK3 in Finland.

[0030] 2. Method

[0031] 2.1 The effect of high glucose on the proliferation of mesangial cells

[0032] Experimental grouping: normal glucose group (NG): the concentration of D-glucose is 5 mmol / L. High glucose group (HG): D-glucose concentration is 30mmol / L. Each group has 6 replicate wells. Hypertonic group (mannitol group): D-glucose (5mmol / L)+mannitol (25mmol / L).

[0033] Experimental method: Cells were inoculated in 96-well cell culture plates ...

Embodiment 21

[0060] Example 21 - Effect of deoxynojirimycin on the expression of α-SMA in rat mesangial cells cultured in high glucose

[0061] 1. Materials and reagents:

[0062] α-smooth muscle actin Wuhan Boster Biological Company, diluted 1:200 with sterile water when used. Rat type IV collagen (type IV collagen), rat fibronectin (Fibronectin, FN) ELISA kits were purchased from Shanghai Senxiong Biological Co., Ltd. UltraSensitive TM S-P immunohistochemical staining kit, diaminobenzidine (DAB) chromogen, Fuzhou Maixin Biotechnology Co., Ltd.

[0063] 2. Method

[0064] 2.1 Experimental grouping and drug intervention training

[0065] Experimental grouping: ① normal glucose group (NG): 5mmol / L D-glucose; ② high glucose group (HG): 30mmol / L D-glucose; ③ mannitol group (M): 5mmol / L D-glucose + 25mmol / L L mannitol; ④ DNJ group: D-glucose 30mmol / L + DNJ 5mmol / L, and a normal glucose negative control group (without primary antibody).

[0066] Drug intervention time: Immunocytochemical...

Embodiment 3

[0075] Example 3 1-deoxynojirimycin on the synthesis of type IV collagen and fibers in rat mesangial cells cultured in high glucose

[0076] The effect of connexin

[0077] 1. Materials and Reagents

[0078] Rat type IV collagen typeIVcollagen, rat fibronectin (Fibronectin) ELISA kits were purchased from Shanghai Senxiong Technology Industrial Co., Ltd.

[0079] 2. Experimental method

[0080] 2.1 ELISA method to determine the expression of type IV collagen and fibronectin

[0081] MSc cells were inoculated in 24-well plates according to conventional methods, and after being synchronized in the G0 phase, they were divided into normal glucose concentration (NG) group: containing D-glucose 5mmol / L; high glucose concentration (HG) group: containing D-glucose 30mmol / L L; Mannitol group (M) group: D-glucose 5mmol / L+25mmol / L mannitol; DNJ group: D-glucose 30mmol / L+1-deoxynojirimycin (DNJ). After 24h, 48h, and 72h of intervening cells, the supernatant was col...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an application of 1-deoxynojirimycin in preparation of medicine for curing diabetes and nephropathy. Said invention also discloses medicine composition for effectively curing diabetes and nephropathy. It contains 1-deoxynojirimycin with safe effective dose and pharmaceutically-acceptable carrier or excipient.

Description

technical field [0001] The invention belongs to the field of pharmacy, and discloses a new medicinal application of 1-deoxynojirimycin. More particularly, the invention relates to the application of 1-deoxynojirimycin in the preparation of drugs for treating diabetic nephropathy and its pharmaceutical composition. Background technique [0002] Diabetic Nephropathy (DN) is one of the most common and serious chronic complications of diabetes. Diabetic nephropathy is the main cause of end-stage renal disease (ESRD) in western countries, and among American dialysis patients DN accounts for 30.0%. At present, the incidence of DN in my country is on the rise, accounting for 13.5% of dialysis patients. Diabetic nephropathy seriously threatens the lives of patients and causes a huge economic burden to society and families. Therefore, it is urgent to clarify the pathogenesis of diabetic kidney in depth, and to enrich and improve the prevention and treatment measures of DN. [0003] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/445
Inventor 原爱红黄哲马骏蒋晓峰吴毅泰
Owner TONGJI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com